Baird served as co-manager on this offering
AboutArrowhead Pharmaceuticals, Inc. (“Arrowhead” or the “Company”) (NASDAQ-GS: ARWR) recently completed an underwritten public offering of 4,600,000 shares of its common stock at a price to the public of $58.00 per share. The gross proceeds to Arrowhead from the offering are expected to be $266.8 million.
Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference, or RNAi, mechanism to induce rapid, deep, and durable knockdown of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. Arrowhead Pharmaceuticals, Inc. is headquartered in Pasadena, California.
CONTACT US TO LEARN MORE
- December 2019
- Arrowhead Pharmaceuticals, Inc.
- Target Location
- North America